Loading…
BridgeBio Oncology Therapeutics, Inc. is projected to rise to $11.31 by 2027, a +28% move from its current price of $8.82. BBOT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/25/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 26 | $8.56 | $8.82 | $9.09 | +0.02% |
| Jul 27 | $8.46 | $8.82 | $9.21 | +0.05% |
| Jul 28 | $8.38 | $8.83 | $9.30 | +0.07% |
| Jul 29 | $8.31 | $8.83 | $9.38 | +0.09% |
| Jul 30 | $8.25 | $8.83 | $9.45 | +0.11% |
| Jul 31 | $8.20 | $8.83 | $9.51 | +0.14% |
| Aug 1 | $8.16 | $8.83 | $9.57 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.16 | $8.83 | $9.57 | +0.16% |
| Week 2 | $7.90 | $8.85 | $9.90 | +0.32% |
| Week 3 | $7.72 | $8.86 | $10.18 | +0.48% |
| Week 4 | $7.57 | $8.88 | $10.41 | +0.64% |
| Week 5 | $7.44 | $8.89 | $10.63 | +0.81% |
| Week 6 | $7.33 | $8.91 | $10.83 | +0.97% |
| Week 7 | $7.22 | $8.92 | $11.01 | +1.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company that develops small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
BBOT is a healthcare stock with a current price of $8.32 and a market capitalization of $666.49M. It is ranked 2827 by market cap. The latest price outlook shows a neutral near-term path in 2026 with an average price of $8.32 and 0% ROI.
The longer-term forecast paints a bullish trajectory into the late 2020s and beyond, with gradual price appreciation and sizable ROI by 2030 and beyond.
A major floor 28.1% below — a decisive break under it would weaken the trend.
The nearest floor, 19.3% below — buyers have tended to step in here.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 16.6% above — clearing it would confirm fresh momentum.
Key BBOT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BBOT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.66 | Buy | $8.69 | Buy |
| MA 10 | $8.57 | Buy | $8.59 | Buy |
| MA 20 | $8.34 | Buy | $8.42 | Buy |
| MA 50 | $8.21 | Buy | $8.37 | Buy |
| MA 100 | $8.61 | Buy | $8.82 | Buy |
| MA 200 | $10.24 | Sell | $9.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.60 | Neutral |
| Stoch RSI (14) | 28.51 | Neutral |
| CCI (20) | 65.79 | Neutral |
| Williams %R (14) | -46.25 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 5.19 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 53.75 | Neutral |
| TRIX (15) | 0.27 | Buy |
| Awesome (5,34) | 0.61 | Buy |
| Ultimate (7,14,28) | 51.68 | Neutral |
| Momentum (10) | -0.37 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 8.80 | Buy |
| ADX (14) | 12.84 | Neutral |
| ATR (14) | 0.25 | Info |
The 30-day technical picture is described as BULLISH. The RSI(14) is 50, and the stock trades around key moving averages with the SMA50 at $8.13 and the SMA200 at $10.38. Near-term support sits at $7.12 and resistance at $9.09, providing a defined trading range. The 30-day range spans from $6.64 to $10.43, offering a measured window for potential moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.12 | $8.82 | $12.11 | 0% | Neutral | |
| $8.93 | $11.31 | $15.21 | +28% | Bullish | |
| $11.21 | $14.65 | $20.51 | +66% | Bullish | |
| $11.31 | $15.18 | $21.93 | +72% | Bullish | |
| $11.16 | $15.32 | $22.72 | +74% | Bullish | |
| $12.20 | $17.11 | $25.97 | +94% | Bullish | |
| $12.09 | $17.29 | $26.79 | +96% | Bullish | |
| $13.00 | $18.93 | $29.89 | +115% | Bullish | |
| $15.67 | $23.22 | $37.29 | +163% | Bullish | |
| $17.42 | $26.25 | $42.84 | +198% | Bullish | |
| $20.82 | $33.86 | $59.04 | +284% | Bullish | |
| $36.83 | $68.47 | $131.41 | +676% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.12 | $8.82 | $10.51 | +0.00% |
| August 2026 | $7.80 | $9.20 | $11.12 | +4.26% |
| September 2026 | $7.58 | $9.01 | $11.04 | -2.06% |
| October 2026 | $7.43 | $8.90 | $11.03 | -1.19% |
| November 2026 | $7.73 | $9.31 | $11.65 | +4.61% |
| December 2026 | $7.92 | $9.60 | $12.11 | +3.07% |
Click any year to see its month-by-month BBOT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BBOT to range from $7.12 to $12.11 through 2026. The $8.82 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The BBOT price prediction for 2027 points to an average of $11.31 (low $8.93, high $15.21) — a potential gain of +28% on today's $8.82. Buyers look set to stay in control over this stretch.
In 2028, BBOT is projected to trade between $11.21 and $20.51, averaging $14.65 — a potential gain of +66% from today's $8.82. That is up +30% on the projected 2027 average. Momentum favours further upside here.
BridgeBio Oncology Therapeutics, Inc.'s 2029 outlook centres on $15.18, within a $11.31 to $21.93 range. That is up +4% on the projected 2028 average. That marks a +72% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, BBOT could reach as high as $22.72, with a base case around $15.32 and support toward $11.16 — roughly +74% from $8.82. Momentum favours further upside here.
Expect BBOT to range from $12.20 to $25.97 through 2031. The $17.11 average target implies a +94% move from current prices. That is up +12% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The BBOT price prediction for 2032 points to an average of $17.29 (low $12.09, high $26.79) — a potential gain of +96% on today's $8.82. Momentum favours further upside here.
In 2033, BBOT is projected to trade between $13.00 and $29.89, averaging $18.93 — a potential gain of +115% from today's $8.82. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
BridgeBio Oncology Therapeutics, Inc.'s 2034 outlook centres on $23.22, within a $15.67 to $37.29 range. That is up +23% on the projected 2033 average. That marks a +163% change versus current levels. Momentum favours further upside here.
By 2035, BBOT could reach as high as $42.84, with a base case around $26.25 and support toward $17.42 — roughly +198% from $8.82. Buyers look set to stay in control over this stretch.
Expect BBOT to range from $20.82 to $59.04 through 2040. The $33.86 average target implies a +284% move from current prices. That is up +29% on the projected 2035 average. Momentum favours further upside here.
The BBOT price prediction for 2050 points to an average of $68.47 (low $36.83, high $131.41) — a potential gain of +676% on today's $8.82. Buyers look set to stay in control over this stretch.
Investing $1,000 in BBOT today (≈ 113.378685 BBOT) could be worth
$7,763.09
+$6,763.09 (+676%) by 2050 · US Dollar
Based on the average projected BBOT price of $68.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BBOTwould be worth at today's price.
$1,000 invested in BBOT on Jul 23, 2025 (≈ 93.545373 BBOT) would be worth
$825.07
-$174.93 (-17.5%) today · 0.83× · US Dollar
Based on a BBOT entry price of $10.69 vs. today's $8.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.31 | $1,061.37 | +6.1% |
| 1 month ago | $7.5 | $1,176 | +17.6% |
| 3 months ago | $8.78 | $1,004.56 | +0.5% |
| 6 months ago | $12.62 | $698.89 | -30.1% |
| 1 year ago | $10.69 | $825.07 | -17.5% |
| All time (2.5y) ago | $10.19 | $865.55 | -13.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BBOT forecast.
Our base-case forecast reaches $18.00 around 2033.
Implied market cap at $18.00: $1.44B
The multi-year forecast shows a bullish trajectory across the horizon. In 2026 the avg price is $8.32 with a min of $7.12 and a max of $11.43 and 0% ROI, sentiment Neutral. By 2027 the avg rises to $10.45 with a min of $8.12 and a max of $14.34 and a 25.6% ROI, sentiment Bullish.
The path continues higher through 2028 with an avg of $13.74 and a 65.2% ROI, then 2029 at $13.63 with 63.8% ROI, and 2030 at $13.64 with 63.9% ROI. Subsequent years show continued gains: 2031 avg $15.39 (84.9% ROI), 2032 avg $14.53 (74.6% ROI), 2033 avg $15.82 (90.1% ROI), 2034 avg $20.07 (141.3% ROI), 2035 avg $22.10 (165.6% ROI). The forecast projects 2040 with avg $27.53 and 230.9% ROI, and 2050 with avg $54.19 and 551.4% ROI.
These figures reflect a bullish longer-term outlook but are estimates, not guarantees, and investors should consider the inherent uncertainty in such projections.
Tap a question to reveal the answer.
The 2027 forecast shows an average price of $10.45, with a range from $8.12 to $14.34 and a 25.6% ROI. The sentiment is bullish.
The forecast indicates a bullish long-term trajectory with rising averages from 2027 onward (e.g., 2027 avg $10.45, 2028 avg $13.74, 2030 avg $13.64, 2050 avg $54.19), but 2026 shows neutral sentiment with 0% ROI. These are estimates, not guarantees.
Yes, according to the forecast, the 2040 max is $50.26 and the 2050 max is $109.77, with the 2050 avg at $54.19 and a 551.4% ROI.
The current price is $8.32 and the market capitalization is $666.49M.
The 30-day picture is bullish with RSI(14) at 50, SMA50 at $8.13, SMA200 at $10.38, support at $7.12, resistance at $9.09, and a 30-day range of $6.64 to $10.43.
BridgeBio Oncology Therapeutics, Inc. Community Discussion
0Share your BridgeBio Oncology Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.